{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T10:49:23Z","timestamp":1787827763216,"version":"build-2784847793"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Monoclonal antibodies are a promising approach to treat COVID-19, however the emergence of SARS-CoV-2 variants has challenged the efficacy and future of these therapies. Antibody cocktails are being employed to mitigate these challenges, but neutralization escape remains a major challenge and alternative strategies are needed. Here we present two anti-SARS-CoV-2 spike binding antibodies, one Class 1 and one Class 4, selected from our non-immune human single-chain variable fragment (scFv) phage library, that are engineered into four, fully-human IgG-like bispecific antibodies (BsAb). Prophylaxis of hACE2 mice and post-infection treatment of golden hamsters demonstrates the efficacy of the monospecific antibodies against the original Wuhan strain, while promising in vitro results with the BsAbs demonstrate enhanced binding and distinct synergistic effects on neutralizing activity against circulating variants of concern. In particular, one BsAb engineered in a tandem scFv-Fc configuration shows synergistic neutralization activity against several variants of concern including B.1.617.2. This work provides evidence that synergistic neutralization can be achieved using a BsAb scaffold, and serves as a foundation for the future development of broadly reactive BsAbs against emerging variants of concern.<\/jats:p>","DOI":"10.1038\/s41467-022-33030-4","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T12:03:17Z","timestamp":1664798597000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["IgG-like bispecific antibodies with potent and synergistic neutralization against circulating SARS-CoV-2 variants of concern"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7244-997X","authenticated-orcid":false,"given":"Matthew R.","family":"Chang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luke","family":"Tomasovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6650-9369","authenticated-orcid":false,"given":"Natalia A.","family":"Kuzmina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8202-9154","authenticated-orcid":false,"given":"Adam J.","family":"Ronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-8951","authenticated-orcid":false,"given":"Patrick O.","family":"Byrne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5104-2919","authenticated-orcid":false,"given":"Rebecca","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2596-0468","authenticated-orcid":false,"given":"Nadia","family":"Storm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduardo","family":"Olmedillas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8323-7243","authenticated-orcid":false,"given":"Yixuan J.","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4760-4923","authenticated-orcid":false,"given":"Alexandra","family":"Sch\u00e4fer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah R.","family":"Leist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7582-8396","authenticated-orcid":false,"given":"Longping V.","family":"Tse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8148-2897","authenticated-orcid":false,"given":"Hanzhong","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Coherd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maliwan","family":"Kamkaew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9165-148X","authenticated-orcid":false,"given":"Anna","family":"Honko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quan","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-9215","authenticated-orcid":false,"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-7451","authenticated-orcid":false,"given":"Erica Ollmann","family":"Saphire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3991-542X","authenticated-orcid":false,"given":"Jason S.","family":"McLellan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5435-8364","authenticated-orcid":false,"given":"Anthony","family":"Griffiths","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6827-8701","authenticated-orcid":false,"given":"Ralph S.","family":"Baric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-4824","authenticated-orcid":false,"given":"Alexander","family":"Bukreyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3764-4611","authenticated-orcid":false,"given":"Wayne A.","family":"Marasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"33030_CR1","doi-asserted-by":"publisher","unstructured":"Lambrou, A. S. et al. Implementation of SARS-CoV-2 monoclonal antibody infusion sites at three medical centers in the United States: strengths and challenges assessment to inform COVID-19 pandemic and future public health emergency use. medRxiv 6, https:\/\/doi.org\/10.1101\/2021.04.05.21254707 (2021).","DOI":"10.1101\/2021.04.05.21254707"},{"key":"33030_CR2","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 596, 276\u2013280 (2021).","journal-title":"Nature"},{"key":"33030_CR3","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1038\/nbt0798-677","volume":"16","author":"AM Merchant","year":"1998","unstructured":"Merchant, A. M. et al. An efficient route to human bispecific IgG. Nat. Biotechnol. 16, 677\u2013681 (1998).","journal-title":"Nat. Biotechnol."},{"key":"33030_CR4","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1093\/protein\/gzp077","volume":"23","author":"KD Orcutt","year":"2010","unstructured":"Orcutt, K. D. et al. A modular IgG-scFv bispecific antibody topology. Protein Eng. Des. Sel. 23, 221\u2013228 (2010).","journal-title":"Protein Eng. Des. Sel."},{"key":"33030_CR5","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1002\/bit.22576","volume":"105","author":"RJ Boado","year":"2010","unstructured":"Boado, R. J., Lu, J. Z., Hui, E. K. W. & Pardridge, W. M. IgG-single chain Fv fusion protein therapeutic for Alzheimer\u2019s disease: expression in CHO cells and pharmacokinetics and brain delivery in the Rhesus monkey. Biotechnol. Bioeng. 105, 627\u2013635 (2010).","journal-title":"Biotechnol. Bioeng."},{"key":"33030_CR6","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1080\/19420862.2016.1162932","volume":"8","author":"A Steinmetz","year":"2016","unstructured":"Steinmetz, A. et al. CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications. MAbs 8, 867\u2013878 (2016).","journal-title":"MAbs"},{"key":"33030_CR7","doi-asserted-by":"publisher","first-page":"6444","DOI":"10.1073\/pnas.90.14.6444","volume":"90","author":"P Holliger","year":"1993","unstructured":"Holliger, P., Prospero, T. & Winter, G. \u2018Diabodies\u2019: small bivalent and bispecific antibody fragments. Proc. Natl Acad. Sci. USA 90, 6444\u20136448 (1993).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"33030_CR8","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1002\/art.27477","volume":"62","author":"MC Veri","year":"2010","unstructured":"Veri, M. C. et al. Therapeutic control of B cell activation via recruitment of Fc\u03b3 receptor IIb (CD32B) inhibitory function with a novel bispecific antibody scaffold. Arthritis Rheum. 62, 1933\u20131943 (2010).","journal-title":"Arthritis Rheum."},{"key":"33030_CR9","doi-asserted-by":"crossref","unstructured":"Ahmad, Z. A. et al. ScFv antibody: Principles and clinical application. Clin. Dev. Immunol. 2012, 980250 (2012).","DOI":"10.1155\/2012\/980250"},{"key":"33030_CR10","unstructured":"Ho, D. 10E8.4\/iMab Bispecific Antibody in HIV-uninfected and HIV-infected Adults (NCT03875209) (2019)."},{"key":"33030_CR11","unstructured":"Bohac, C. MGD014 in HIV-Infected Individuals on Suppressive Antiretroviral Therapy (NCT03570918) (2018)."},{"key":"33030_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","volume":"27","author":"RM Lu","year":"2020","unstructured":"Lu, R. M. et al. Development of therapeutic antibodies for the treatment of diseases. J. Biomed. Sci. 27, 1\u201330 (2020).","journal-title":"J. Biomed. Sci."},{"key":"33030_CR13","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1016\/j.cell.2016.04.050","volume":"165","author":"S Bournazos","year":"2016","unstructured":"Bournazos, S., Gazumyan, A., Seaman, M. S., Nussenzweig, M. C. & Ravetch, J. V. Bispecific Anti-HIV-1 antibodies with enhanced breadth and potency. Cell 165, 1609\u20131620 (2016).","journal-title":"Cell"},{"key":"33030_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12977-019-0493-y","volume":"16","author":"T Moshoette","year":"2019","unstructured":"Moshoette, T., Ali, S. A., Papathanasopoulos, M. A. & Killick, M. A. Engineering and characterising a novel, highly potent bispecific antibody iMab-CAP256 that targets HIV-1. Retrovirology 16, 1\u201312 (2019).","journal-title":"Retrovirology"},{"key":"33030_CR15","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1128\/JVI.00078-15","volume":"89","author":"M Zanin","year":"2015","unstructured":"Zanin, M. et al. An anti-H5N1 influenza virus FcDART antibody is a highly efficacious therapeutic agent and prophylactic against H5N1 influenza virus infection. J. Virol. 89, 4549\u20134561 (2015).","journal-title":"J. Virol."},{"key":"33030_CR16","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/srep19193","volume":"6","author":"JC Frei","year":"2016","unstructured":"Frei, J. C. et al. Bispecific antibody affords complete post-exposure protection of mice from both Ebola (Zaire) and Sudan viruses. Sci. Rep. 6, 2\u201311 (2016).","journal-title":"Sci. Rep."},{"key":"33030_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1126\/science.abb7269","volume":"368","author":"M Yuan","year":"2020","unstructured":"Yuan, M. et al. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2 and SARS-CoV. Science 368, 630\u2013633 (2020).","journal-title":"Science"},{"key":"33030_CR18","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1126\/science.1085953","volume":"300","author":"MA Marra","year":"2003","unstructured":"Marra, M. A. et al. The Genome sequence of the SARS-associated coronavirus. Science 300, 1399\u20131404 (2003).","journal-title":"Science"},{"key":"33030_CR19","first-page":"1","volume":"8","author":"NYL Pang","year":"2021","unstructured":"Pang, N. Y. L., Pang, A. S. R., Chow, V. T. & Wang, D. Y. Understanding neutralising antibodies against SARS-CoV-2 and their implications in clinical practice. Mil. Med. Res. 8, 1\u201317 (2021).","journal-title":"Mil. Med. Res."},{"key":"33030_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bbrc.2021.06.001","volume":"566","author":"D Jin","year":"2021","unstructured":"Jin, D., Wei, J. & Sun, J. Analysis of the molecular mechanism of SARS-CoV-2 antibodies. Biochem. Biophys. Res. Commun. 566, 45\u201352 (2021).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"33030_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fimmu.2021.647934","volume":"12","author":"L Niu","year":"2021","unstructured":"Niu, L., Wittrock, K. N., Clabaugh, G. C., Srivastava, V. & Cho, M. W. A structural landscape of neutralizing antibodies against SARS-CoV-2 receptor binding domain. Front. Immunol. 12, 1\u20136 (2021).","journal-title":"Front. Immunol."},{"key":"33030_CR22","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1016\/j.it.2020.09.004","volume":"41","author":"E Gavor","year":"2020","unstructured":"Gavor, E., Choong, Y. K., Er, S. Y., Sivaraman, H. & Sivaraman, J. Structural basis of SARS-CoV-2 and SARS-CoV antibody interactions. Trends Immunol. 41, 1006\u20131022 (2020).","journal-title":"Trends Immunol."},{"key":"33030_CR23","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1126\/science.abc7424","volume":"369","author":"AZ Wec","year":"2020","unstructured":"Wec, A. Z. et al. Broad neutralization of SARS-related viruses by human monoclonal antibodies. Science 369, 731\u2013736 (2020).","journal-title":"Science"},{"key":"33030_CR24","first-page":"e9","volume":"29","author":"AJ Greaney","year":"2021","unstructured":"Greaney, A. J. et al. Complete mapping of mutations to the SARS-CoV-2 spike receptor-binding domain that escape antibody recognition. Cell Host Microbe 29, e9 (2021).","journal-title":"Cell Host Microbe"},{"key":"33030_CR25","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1038\/s41564-021-00972-2","volume":"6","author":"J Dong","year":"2021","unstructured":"Dong, J. et al. Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. Nat. Microbiol. 6, 1233\u20131244 (2021).","journal-title":"Nat. Microbiol."},{"key":"33030_CR26","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","volume":"19","author":"WT Harvey","year":"2021","unstructured":"Harvey, W. T. et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 19, 409\u2013424 (2021).","journal-title":"Nat. Rev. Microbiol."},{"key":"33030_CR27","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1126\/science.abh2315","volume":"374","author":"KM Hastie","year":"2021","unstructured":"Hastie, K. M. et al. Defining variant-resistant epitopes targeted by SARS-CoV-2 antibodies: a global consortium study. Science 374, 472\u2013478 (2021).","journal-title":"Science"},{"key":"33030_CR28","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/s41586-021-03817-4","volume":"597","author":"MA Tortorici","year":"2021","unstructured":"Tortorici, M. A. et al. Broad sarbecovirus neutralization by a human monoclonal antibody. Nature 597, 103\u2013108 (2021).","journal-title":"Nature"},{"key":"33030_CR29","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41586-020-2342-5","volume":"583","author":"SF Sia","year":"2020","unstructured":"Sia, S. F. et al. Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. Nature 583, 834\u2013838 (2020).","journal-title":"Nature"},{"key":"33030_CR30","doi-asserted-by":"publisher","first-page":"16587","DOI":"10.1073\/pnas.2009799117","volume":"117","author":"M Imai","year":"2020","unstructured":"Imai, M. et al. Syrian hamsters as a small animal model for SARS-CoV-2 infection and countermeasure development. Proc. Natl Acad. Sci. 117, 16587\u201316595 (2020).","journal-title":"Proc. Natl Acad. Sci."},{"key":"33030_CR31","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4161\/rna.8.2.15013","volume":"8","author":"MR Denison","year":"2011","unstructured":"Denison, M. R., Graham, R. L., Donaldson, E. F., Eckerle, L. D. & Baric, R. S. Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol. 8, 270\u2013279 (2011).","journal-title":"RNA Biol."},{"key":"33030_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.ppat.1009226","volume":"17","author":"J Gribble","year":"2021","unstructured":"Gribble, J. et al. The coronavirus proofreading exoribonuclease mediates extensive viral recombination. PLoS Pathog. 17, 1\u201328 (2021).","journal-title":"PLoS Pathog."},{"key":"33030_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02344-6","volume":"18","author":"M Pachetti","year":"2020","unstructured":"Pachetti, M. et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. J. Transl. Med. 18, 1\u20139 (2020).","journal-title":"J. Transl. Med."},{"key":"33030_CR34","doi-asserted-by":"publisher","first-page":"710","DOI":"10.1016\/j.molcel.2020.07.027","volume":"79","author":"F Robson","year":"2020","unstructured":"Robson, F. et al. Coronavirus RNA proofreading: molecular basis and therapeutic targeting. Mol. Cell 79, 710\u2013727 (2020).","journal-title":"Mol. Cell"},{"key":"33030_CR35","doi-asserted-by":"crossref","unstructured":"Miao, M., De Clercq, E. & Li, G. Genetic diversity of sars-cov-2 over a one-year period of the covid-19 pandemic: a global perspective. Biomedicines 9, 412 (2021).","DOI":"10.3390\/biomedicines9040412"},{"key":"33030_CR36","unstructured":"Lythgoe, K. A. et al. SARS-CoV-2 within-host diversity and transmission. Science 372, eabg0821 (2021)."},{"key":"33030_CR37","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41586-020-2708-8","volume":"586","author":"KH Dinnon","year":"2020","unstructured":"Dinnon, K. H. et al. A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures. Nature 586, 560\u2013566 (2020).","journal-title":"Nature"},{"key":"33030_CR38","doi-asserted-by":"publisher","first-page":"108630","DOI":"10.1016\/j.celrep.2020.108630","volume":"34","author":"SMC Gobeil","year":"2021","unstructured":"Gobeil, S. M. C. et al. D614G mutation alters SARS-CoV-2 spike conformation and enhances protease cleavage at the S1\/S2 junction. Cell Rep. 34, 108630 (2021).","journal-title":"Cell Rep."},{"key":"33030_CR39","doi-asserted-by":"crossref","unstructured":"Ozono, S. et al. SARS-CoV-2 D614G spike mutation increases entry efficiency with enhanced ACE2-binding affinity. Nat. Commun. 12, 848 (2021).","DOI":"10.1038\/s41467-021-21118-2"},{"key":"33030_CR40","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1126\/science.abf2303","volume":"372","author":"J Zhang","year":"2021","unstructured":"Zhang, J. et al. Structural impact on SARS-CoV-2 spike protein by D614G substitution. Science 372, 525\u2013530 (2021).","journal-title":"Science"},{"key":"33030_CR41","unstructured":"Tracking SARS-CoV-2 variants. World Health Organization https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/ (2021)."},{"key":"33030_CR42","doi-asserted-by":"crossref","unstructured":"Lazarevic, I., Pravica, V., Miljanovic, D. & Cupic, M. Immune evasion of sars\u2010cov\u20102 emerging variants: What have we learnt so far? Viruses 13, 1192 (2021).","DOI":"10.3390\/v13071192"},{"key":"33030_CR43","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0261045","volume":"17","author":"PL Tzou","year":"2022","unstructured":"Tzou, P. L., Tao, K., Kosakovsky Pond, S. L. & Shafer, R. W. Coronavirus Resistance Database (CoV-RDB): SARS-CoV-2 susceptibility to monoclonal antibodies, convalescent plasma, and plasma from vaccinated persons. PLoS ONE 17, 1\u201320 (2022).","journal-title":"PLoS ONE"},{"key":"33030_CR44","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1016\/j.immuni.2021.03.023","volume":"54","author":"C Graham","year":"2021","unstructured":"Graham, C. et al. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant. Immunity 54, 1276\u20131289.e6 (2021).","journal-title":"Immunity"},{"key":"33030_CR45","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/s41591-021-01318-5","volume":"27","author":"D Planas","year":"2021","unstructured":"Planas, D. et al. Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. Nat. Med. 27, 917\u2013924 (2021).","journal-title":"Nat. Med."},{"key":"33030_CR46","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41586-021-03398-2","volume":"593","author":"P Wang","year":"2021","unstructured":"Wang, P. et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature 593, 130\u2013135 (2021).","journal-title":"Nature"},{"key":"33030_CR47","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1016\/j.cell.2021.03.036","volume":"184","author":"M Hoffmann","year":"2021","unstructured":"Hoffmann, M. et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell 184, 2384\u20132393.e12 (2021).","journal-title":"Cell"},{"key":"33030_CR48","doi-asserted-by":"publisher","unstructured":"Liu, Y. et al. Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes. bioRxiv 1\u201322 https:\/\/doi.org\/10.1101\/2021.09.02.458740 (2021).","DOI":"10.1101\/2021.09.02.458740"},{"key":"33030_CR49","unstructured":"Chou, T.-C. & Martin, N. CompuSyn software for drug combinations and for general dose- effect analysis, and user\u2019s guide. ComboSyn, Inc. Paramus, NJ 2007. www.combosyn.com (2007)."},{"key":"33030_CR50","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1038\/72309","volume":"6","author":"TW Baba","year":"2000","unstructured":"Baba, T. W. et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian\u2013human immunodeficiency virus infection. Nat. Med. 6, 200\u2013206 (2000).","journal-title":"Nat. Med."},{"key":"33030_CR51","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.synres.2018.04.001","volume":"7","author":"T-C Chou","year":"2018","unstructured":"Chou, T.-C. The combination index (CI < 1) as the definition of synergism and of synergy claims. Synergy 7, 49\u201350 (2018).","journal-title":"Synergy"},{"key":"33030_CR52","doi-asserted-by":"publisher","first-page":"e1009885","DOI":"10.1371\/journal.ppat.1009885","volume":"17","author":"S Kumar","year":"2021","unstructured":"Kumar, S., Chandele, A. & Sharma, A. Current status of therapeutic monoclonal antibodies against SARS-CoV-2. PLOS Pathog. 17, e1009885 (2021).","journal-title":"PLOS Pathog."},{"key":"33030_CR53","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1016\/j.cell.2021.05.005","volume":"184","author":"D Corti","year":"2021","unstructured":"Corti, D., Purcell, L. A., Snell, G. & Veesler, D. Tackling COVID-19 with neutralizing monoclonal antibodies. Cell 184, 3086\u20133108 (2021).","journal-title":"Cell"},{"key":"33030_CR54","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.chom.2021.01.014","volume":"29","author":"Z Liu","year":"2021","unstructured":"Liu, Z. et al. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe 29, 477\u2013488.e4 (2021).","journal-title":"Cell Host Microbe"},{"key":"33030_CR55","doi-asserted-by":"publisher","unstructured":"Cyrus Maher, M. et al. Predicting the mutational drivers of future SARS-CoV-2 variants of concern. medRxiv https:\/\/doi.org\/10.1101\/2021.06.21.21259286 (2021).","DOI":"10.1101\/2021.06.21.21259286"},{"key":"33030_CR56","unstructured":"Hinton, D. Emergency Use Authorization 094. FDA vol. 26 (2021)."},{"key":"33030_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12967-020-02675-4","volume":"18","author":"A Massacci","year":"2020","unstructured":"Massacci, A. et al. Design of a companion bioinformatic tool to detect the emergence and geographical distribution of SARS-CoV-2 Spike protein genetic variants. J. Transl. Med. 18, 1\u20137 (2020).","journal-title":"J. Transl. Med."},{"key":"33030_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0022-2836(03)00372-3","volume":"329","author":"HX Zhou","year":"2003","unstructured":"Zhou, H. X. Quantitative account of the enhanced affinity of two linked scFvs specific for different epitopes on the same antigen. J. Mol. Biol. 329, 1\u20138 (2003).","journal-title":"J. Mol. Biol."},{"key":"33030_CR59","doi-asserted-by":"publisher","unstructured":"Tada, T. et al. Decreased neutralization of SARS-CoV-2 global variants by therapeutic anti-spike protein monoclonal antibodies. bioRxiv https:\/\/doi.org\/10.1101\/2021.02.18.4318977 (2021).","DOI":"10.1101\/2021.02.18.4318977"},{"key":"33030_CR60","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41586-021-03461-y","volume":"593","author":"R De Gasparo","year":"2021","unstructured":"De Gasparo, R. et al. Bispecific IgG neutralizes SARS-CoV-2 variants and prevents escape in mice. Nature 593, 424\u2013428 (2021).","journal-title":"Nature"},{"key":"33030_CR61","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41590-022-01138-w","volume":"23","author":"Z Li","year":"2022","unstructured":"Li, Z. et al. An engineered bispecific human monoclonal antibody against SARS-CoV-2. Nat. Immunol. 23, 423\u2013430 (2022).","journal-title":"Nat. Immunol."},{"key":"33030_CR62","doi-asserted-by":"crossref","unstructured":"Cho, H. et al. Bispecific antibodies targeting distinct regions of the spike protein potently neutralize SARS-CoV-2 variants of concern. Sci. Transl. Med. 13, eabj5413 (2021).","DOI":"10.1126\/scitranslmed.abj5413"},{"key":"33030_CR63","doi-asserted-by":"publisher","unstructured":"Ku, Z. et al. Engineering SARS-CoV-2 cocktail antibodies into a bispecific format improves neutralizing potency and breadth. bioRxiv https:\/\/doi.org\/10.1101\/2022.02.01.478504 (2022).","DOI":"10.1101\/2022.02.01.478504"},{"key":"33030_CR64","doi-asserted-by":"publisher","unstructured":"Jones, B. E. et al. LY-CoV555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human primate model of SARS-CoV-2 infection. bioRxiv 1\u201329 https:\/\/doi.org\/10.1101\/2020.09.30.318972 (2020).","DOI":"10.1101\/2020.09.30.318972"},{"key":"33030_CR65","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1126\/science.abd0827","volume":"369","author":"J Hansen","year":"2020","unstructured":"Hansen, J. et al. Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail. Science 369, 1010\u20131014 (2020).","journal-title":"Science"},{"key":"33030_CR66","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1073\/pnas.0307140101","volume":"101","author":"J Sui","year":"2004","unstructured":"Sui, J. et al. Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association. Proc. Natl Acad. Sci. 101, 2536\u20132541 (2004).","journal-title":"Proc. Natl Acad. Sci."},{"key":"33030_CR67","doi-asserted-by":"publisher","first-page":"5900","DOI":"10.1128\/JVI.79.10.5900-5906.2005","volume":"79","author":"J Sui","year":"2005","unstructured":"Sui, J. et al. Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J. Virol. 79, 5900\u20135906 (2005).","journal-title":"J. Virol."},{"key":"33030_CR68","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/nsmb.1566","volume":"16","author":"J Sui","year":"2009","unstructured":"Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265\u2013273 (2009).","journal-title":"Nat. Struct. Mol. Biol."},{"key":"33030_CR69","doi-asserted-by":"crossref","unstructured":"Tang, X. C. et al. Identification of human neutralizing antibodies against MERS-CoV and their role in virus adaptive evolution. Proc. Natl. Acad. Sci. 111, E2018-26 (2014).","DOI":"10.1073\/pnas.1402074111"},{"key":"33030_CR70","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1126\/science.abf9302","volume":"371","author":"TN Starr","year":"2021","unstructured":"Starr, T. N. et al. Prospective mapping of viral mutations that escape antibodies used to treat COVID-19. Science 371, 850\u2013854 (2021).","journal-title":"Science"},{"key":"33030_CR71","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.cell.2020.08.012","volume":"182","author":"TN Starr","year":"2020","unstructured":"Starr, T. N. et al. Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding. Cell 182, 1295\u20131310.e20 (2020).","journal-title":"Cell"},{"key":"33030_CR72","doi-asserted-by":"crossref","unstructured":"Beverly, L. J., Lockwood, W. W., Shah, P. P., Erdjument-Bromage, H. & Varmus, H. Ubiquitination, localization, and stability of an anti-apoptotic BCL2-like protein, BCL2L10\/BCLb, are regulated by Ubiquilin1. Proc. Natl. Acad. Sci. USA 109, E119\u2013E126 (2012).","DOI":"10.1073\/pnas.1119167109"},{"key":"33030_CR73","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1038\/s41592-019-0580-y","volume":"16","author":"D Tegunov","year":"2019","unstructured":"Tegunov, D. & Cramer, P. Real-time cryo-electron microscopy data preprocessing with Warp. Nat. Methods 16, 1146\u20131152 (2019).","journal-title":"Nat. Methods"},{"key":"33030_CR74","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/nmeth.4169","volume":"14","author":"A Punjani","year":"2017","unstructured":"Punjani, A., Rubinstein, J. L., Fleet, D. J. & Brubaker, M. A. CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination. Nat. Methods 14, 290\u2013296 (2017).","journal-title":"Nat. Methods"},{"key":"33030_CR75","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.3201\/eid2606.200516","volume":"26","author":"J Harcourt","year":"2020","unstructured":"Harcourt, J. et al. Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. Emerg. Infect. Dis. 26, 1266\u20131273 (2020).","journal-title":"Emerg. Infect. Dis."},{"key":"33030_CR76","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/j.chom.2020.04.004","volume":"27","author":"X Xie","year":"2020","unstructured":"Xie, X. et al. An Infectious cDNA Clone of SARS-CoV-2. Cell Host Microbe 27, 841\u2013848.e3 (2020).","journal-title":"Cell Host Microbe"},{"key":"33030_CR77","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.cell.2020.05.042","volume":"182","author":"YJ Hou","year":"2020","unstructured":"Hou, Y. J. et al. SARS-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tract. Cell 182, 429\u2013446.e14 (2020).","journal-title":"Cell"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33030-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33030-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33030-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,28]],"date-time":"2023-11-28T10:15:30Z","timestamp":1701166530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-33030-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":77,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["33030"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-33030-4","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]},"assertion":[{"value":"26 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 August 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5814"}}